Boston Scientific (NYSE:BSX) has reported first-quarter revenue and earnings that beat its own guidance as well as Wall Street’s expectations due to strong growth at its MedSurg and Cardiovascular units, sending its shares higher in pre-market trading.
The Marlborough, Massachusetts-based medical products company said net sales increased 12% to $3.39 billion on a reported basis for the three months to March 31, 2023, above its guidance range of 3% to 5%.
MedSurg, which includes medical devices designed and manufactured for Endoscopy, and Urology & Women’s Health, grew sales by 11% on a reported basis, while net sales at Cardiovascular jumped 12.7%.
Sales growth was strongest in emerging markets, with Latin America and Canada also showing good momentum.
Adjusted earnings per share of $0.47 were ahead of the $0.42 to $0.44 it predicted and also above the $0.43 analyst consensus forecast.
“I'm pleased with our excellent results this quarter, which highlight our team's strong performance across each business and region," chairman and CEO Mike Mahoney, said in an earnings statement.
1Q highlights
Highlights of the quarter included the launch in the US and Japan of its LithoVue Elite Single-Use Digital Flexible Ureteroscope System following US Food and Drug Administration clearance.
It also received approval from Japanese Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada and CE Mark for its POLARx FIT Cryoablation Balloon Catheter.
During the quarter, it also announced real-world outcomes from the SURPASS one-year analysis of more than 66,000 patients with its WATCHMAN FLX Left Atrial Appendage Closure Device.
"With a robust pipeline in 2023 and beyond, I'm optimistic about our ability to continue to deliver differentiated financial performance and the opportunity to reach more patients with life-changing therapies,” Mahoney added.
The company’s shares were 3.7% higher in pre-market trading.
Contact the author at stephen.gunnion@proactiveinvestors.com